0001213900-14-003729.txt : 20140522 0001213900-14-003729.hdr.sgml : 20140522 20140522111130 ACCESSION NUMBER: 0001213900-14-003729 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140522 DATE AS OF CHANGE: 20140522 EFFECTIVENESS DATE: 20140522 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Relmada Therapeutics, Inc. CENTRAL INDEX KEY: 0001554535 IRS NUMBER: 208506626 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-217828 FILM NUMBER: 14862651 BUSINESS ADDRESS: STREET 1: 146 MEDINAH DRIVE CITY: BLUE BELL STATE: PA ZIP: 19422 BUSINESS PHONE: 610-272-2071 MAIL ADDRESS: STREET 1: 146 MEDINAH DRIVE CITY: BLUE BELL STATE: PA ZIP: 19422 D 1 primary_doc.xml X0707 D LIVE 0001554535 Relmada Therapeutics, Inc. 546 FIFTH AVENUE 14TH FLOOR NEW YORK NY NEW YORK 10036 (212) 702-7163 DELAWARE TheraQuest Biosciences, Inc. None Corporation true Sergio Traversa 546 Fifth Avenue 14th Floor New York NY NEW YORK 10036 Executive Officer Director Chief Executive Officer Eliseo O. Salinas 546 Fifth Avenue 14th Floor New York NY NEW YORK 10036 Executive Officer President and Chief Scientific Officer Douglas Beck 546 Fifth Avenue 14th Floor New York NY NEW YORK 10036 Executive Officer Chief Financial Officer Sandesh Seth 546 Fifth Avenue 14th Floor New York NY NEW YORK 10036 Director Lead Director Shreeram Agharkar 546 Fifth Avenue 14th Floor New York NY NEW YORK 10036 Director Nabil M. Yazgi 546 Fifth Avenue 14th Floor New York NY NEW YORK 10036 Director Biotechnology No Revenues 06b false 2014-05-12 false true true false 100000 Laidlaw & Company (UK) Ltd. 119037 None None 546 FIFTH AVENUE 5TH FLOOR NEW YORK NY NEW YORK 10036 AL ALABAMA AZ ARIZONA AR ARKANSAS CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA GA GEORGIA IL ILLINOIS KS KANSAS LA LOUISIANA MD MARYLAND MA MASSACHUSETTS MI MICHIGAN MO MISSOURI NH NEW HAMPSHIRE NJ NEW JERSEY NY NEW YORK NC NORTH CAROLINA OH OHIO OR OREGON PA PENNSYLVANIA RI RHODE ISLAND TX TEXAS VA VIRGINIA WV WEST VIRGINIA false 15051110 15051110 0 false 225 1806133 0 Included in the sales commission amount is a non-accountable 2% allowance for expenses paid to the agent. The agent also received warrants to purchase 25,085,183 shares of common stock of the issuer. 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false Relmada Therapeutics, Inc. /s/ Sergio Traversa Sergio Traversa Chief Executive Officer 2014-05-22